An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00904657
Recruitment Status : Completed
First Posted : May 20, 2009
Last Update Posted : December 4, 2009
University Hospital, Bonn
ZKS Köln
Information provided by:
University of Cologne

Brief Summary:

The study is conducted:

  • to investigate the influence of sunitinib (study drug) on the plasma biomarkers VEGF-A, VEGF-C, soluble VEGFR-2, and soluble VEGFR-3 (vessel endothelial growth factors) and on the blood pressure;
  • to generate a pharmacokinetic/pharmacodynamic model for sunitinib using biomarkers.

Condition or disease Intervention/treatment Phase
Blood Pressure Drug: sunitinib (Sutent) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-label One-way Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers
Study Start Date : October 2008
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: sunitinib (Sutent)
    50 mg capsule Sutent, one application a day for five days

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Caucasian
  • Male/Female
  • Age: 18-55 years
  • Body weight of 60 kg or higher, Body Mass Index 19 - 27 kg/m2
  • Considered to be healthy on the basis of extensive pre-study screening
  • Willing and capable to confirm written consent to enrolment after ample information has been provided

Exclusion Criteria:

  • Ongoing healing of wound or parenchymal tissue requiring angiogenesis
  • Any skin abnormality and/or neurodermatitis and /or chronic skin disease
  • A history of haemorrhage
  • A history of any gastrointestinal event with persisting clinical relevance
  • A history of pancreatitis
  • History of cerebrovascular accident or transient ischemic attack or seizures
  • History of pulmonary embolism
  • History of venous thromboembolic events
  • History of hypertension
  • A history of cardiac events within 12 months prior to sunitinib administration such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft
  • Any relevant clinical abnormality (as based on extensive medical history, amination, vital signs and 12-lead ECG)
  • Inadequate cardiac function [left ventricular ejection fraction (LVEF) < lower limit of normal (LLN) as assessed by echocardiography (ECHO)]
  • A history of any surgical abdominal intervention (including appendectomy) or of peritonitis
  • Bronchial asthma, COPD, or actual obstructive bronchitis
  • Hypothyroidism /hyperthyroidism
  • Cardiac insufficiency
  • Liver disease
  • Cardiac dysrhythmia (e.g., prolongation of the QT interval)
  • Diabetes mellitus
  • Chronic infections
  • Relevant acute infections or with actual therapy-requiring allergies (including drug allergies) within the last two weeks
  • Suspicion of hypersensitivity to sunitinib or to any of the excipients
  • Any clinically relevant laboratory abnormality
  • Subjects receiving any medication within 2 weeks prior to study start or during the study (exceptions possible upon decision of Principal Investigator, e.g., paracetamol (acetaminophen) single dose for acute pain or topical aciclovir for herpes simplex)
  • Subjects who have taken a drug with a long half-life (> 24 hours) within four weeks before the first trial day
  • Subjects who received chronic drug treatment (> 3 days) within eight weeks before the first trial day
  • Subjects who participated in a clinical trial within the last 3 months before the start of the present study
  • Subjects who donated blood or plasma within the last 12 weeks before the start of the present study
  • Subjects who smoke, i.e., subjects who smoked one or more cigarettes during the last six months
  • Subjects who are known or suspected to be (social) drug dependent, incl. those drinking more than 30 g alcohol per day
  • Subjects with a history of alcohol or recreational drug addiction
  • Subjects with a history of any severe disease that might interfere with the study objectives (e.g. psychiatric disease, epilepsy)
  • Subjects who are not willing or able to abstain from alcohol, methylxanthine-containing beverages and foods, and grapefruit flesh/juice for 72 hours before first study drug administration until 2 weeks after last study drug administration
  • Subjects who adhere to a special diet (e.g., vegetarians) or lifestyle (including working at night and extreme physical activities such as competitive sports and weight lifting) that might interfere with the investigation
  • Subjects planning elective hospital treatment within two months after last intake of trial medication
  • Subjects who are known or suspected not to comply with the study directives and/or known or suspected not to be reliable or trustworthy
  • Subjects who are known or suspected not to be capable of understanding and evaluating the information that is given to them as part of the formal information policy (informed consent), in particular regarding the foreseeable risks and discomfort to which they will be exposed
  • Subjects with anticipated problems of successfully placing an indwelling venous catheter at a forearm
  • Female subjects only:

    • positive results in pregnancy test
    • pregnant and lactating women
    • subjects who do not use or does not agree to use appropriate contraceptive methods during the study and two months after the study
  • Male subjects only: they have to accept not to procreate children during the study and two months after the study

Responsible Party: Prof. Dr. Med. U. Fuhr, University of Cologne Identifier: NCT00904657     History of Changes
Other Study ID Numbers: Uni-Koeln-1127
First Posted: May 20, 2009    Key Record Dates
Last Update Posted: December 4, 2009
Last Verified: December 2009

Keywords provided by University of Cologne:
pharmacokinetic/pharmacodynamic modeling
biomarkers (growth factors) as a possible tool of drug effect

Additional relevant MeSH terms:
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors